Dr. Reddy's to Release Q4 and Full Year FY 19 Results on May 17, 2019
April 17 2019 - 12:05PM
Business Wire
Earnings call slated for May 17, 6:00 PM IST
/ 8:30 AM EDT
Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY)
(NYSE: RDY) will announce results for the fourth quarter and full
year ended March 31, 2019 on Friday, May 17, 2019 after the Board
Meeting.
Summary of Events
Event Date and
Time Medium Release of financial results
May 17th, after the Board Meeting
Email, Media, Company website, Business
Wire
Press meet presentation
Will be available on the Company’s
website
URL available on Company’s website,
www.drreddys.com
Earnings Call May 17th, 6:00 PM IST / 8:30 AM EDT
Hosted by the Company (Details below)
Playback of Earnings Call After the earnings call till May
24th, 2019 Details below Transcript of the Earnings call
Will be available on the Company’s website
URL available on Company’s website,
www.drreddys.com
Earnings Call
Following the release, the management of the Company will host
an earnings call to discuss the Company’s financial performance.
(Dial In and other details given below)
Play Back
The play back will be available after the earnings call, till
May 24th, 2019. For play back dial in phone No: 022 7194 5757 / 022
6663 5757, and Playback Code is 04147.
Conference Dial-In Numbers Universal Access Number:
+91 22 6280 1219
+91 22 7115 8120
Local Access Number:
Available all over India
+91 70456 71221 International Toll Free Number:
USA:
1 866 746 2133
UK: 0 808 101 1573
Singapore: 800 101 2045
Hong Kong: 800 964 448
No password/pin number is necessary to dial in to any of the
above numbers. The operator will provide instructions on asking
questions before and during the call.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124) (NSE: DRREDDY) (NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr Reddy’s operates in
markets across the globe. Our Major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com.
Disclaimer: This press release may include statements of
future expectations and other forward-looking statements that are
based on the management’s current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual
results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements
which are forward-looking by reason of context, the words "may,"
"will," "should," "expects," "plans," "intends," "anticipates,"
"believes," "estimates," "predicts," "potential," or "continue" and
similar expressions identify forward-looking statements. Actual
results, performance or events may differ materially from those in
such statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults, currency exchange rates, interest rates, persistency
levels and frequency/severity of insured loss events, (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization,
including related integration issues.
The company assumes no obligation to update any information
contained herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190417005668/en/
INVESTOR RELATIONSAMIT AGARWALamita@drreddys.com(Ph:
+91-40-49002135)
MEDIA RELATIONSMITALI
SARKARmitali.sarkar@drreddys.com(Ph:
+91-40-49002121)
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2023 to Apr 2024